Halozyme Therapeutics, Inc. (HALO)
HALO Stock Price Chart
Explore Halozyme Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze HALO price movements and trends.
HALO Company Profile
Discover essential business fundamentals and corporate details for Halozyme Therapeutics, Inc. (HALO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 Mar 2004
Employees
350.00
Website
https://www.halozyme.comCEO
Helen I. Torley M.B. Ch. B., M.R.C.P.
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
HALO Financial Timeline
Browse a chronological timeline of Halozyme Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Oct 2025
EPS estimate is $1.63, while revenue estimate is $339.74M.
Earnings released on 5 Aug 2025
EPS came in at $1.54 surpassing the estimated $1.23 by +25.20%, while revenue for the quarter reached $325.72M , missing expectations by -1.53%.
Earnings released on 6 May 2025
EPS came in at $1.11 surpassing the estimated $0.95 by +16.84%, while revenue for the quarter reached $264.86M , missing expectations by -5.73%.
Earnings released on 18 Feb 2025
EPS came in at $1.26 surpassing the estimated $1.17 by +7.69%, while revenue for the quarter reached $298.01M , beating expectations by +4.29%.
Earnings released on 31 Oct 2024
EPS came in at $1.27 surpassing the estimated $0.98 by +29.59%, while revenue for the quarter reached $290.08M , missing expectations by -0.94%.
Earnings released on 6 Aug 2024
EPS came in at $0.91 surpassing the estimated $0.76 by +19.74%, while revenue for the quarter reached $231.35M , beating expectations by +10.73%.
Earnings released on 7 May 2024
EPS came in at $0.79 surpassing the estimated $0.70 by +12.86%, while revenue for the quarter reached $195.88M , missing expectations by -1.95%.
Earnings released on 20 Feb 2024
EPS came in at $0.82 falling short of the estimated $0.83 by -1.20%, while revenue for the quarter reached $230.04M , missing expectations by -0.48%.
Earnings released on 6 Nov 2023
EPS came in at $0.75 surpassing the estimated $0.71 by +5.63%, while revenue for the quarter reached $216.03M , missing expectations by -2.96%.
Earnings released on 8 Aug 2023
EPS came in at $0.74 surpassing the estimated $0.63 by +17.46%, while revenue for the quarter reached $221.04M , beating expectations by +10.55%.
Earnings released on 9 May 2023
EPS came in at $0.47 falling short of the estimated $0.48 by -2.08%, while revenue for the quarter reached $162.14M , missing expectations by -7.62%.
Earnings released on 21 Feb 2023
EPS came in at $0.48 surpassing the estimated $0.47 by +2.13%, while revenue for the quarter reached $181.50M , missing expectations by -5.50%.
Earnings released on 8 Nov 2022
EPS came in at $0.74 surpassing the estimated $0.52 by +42.31%, while revenue for the quarter reached $208.98M , beating expectations by +9.31%.
Earnings released on 9 Aug 2022
EPS came in at $0.53 surpassing the estimated $0.50 by +6.00%, while revenue for the quarter reached $152.37M , beating expectations by +9.91%.
Earnings released on 10 May 2022
EPS came in at $0.47 falling short of the estimated $0.49 by -4.08%, while revenue for the quarter reached $117.28M , missing expectations by -8.56%.
Earnings released on 22 Feb 2022
EPS came in at $0.42 surpassing the estimated $0.41 by +2.44%, while revenue for the quarter reached $102.00M , beating expectations by +0.46%.
Earnings released on 2 Nov 2021
EPS came in at $0.55 surpassing the estimated $0.42 by +30.95%, while revenue for the quarter reached $115.83M , beating expectations by +8.29%.
Earnings released on 9 Aug 2021
EPS came in at $0.62 surpassing the estimated $0.41 by +51.22%, while revenue for the quarter reached $136.46M , beating expectations by +31.16%.
Earnings released on 10 May 2021
EPS came in at $0.37 surpassing the estimated $0.31 by +19.35%, while revenue for the quarter reached $89.02M , beating expectations by +6.00%.
Earnings released on 23 Feb 2021
EPS came in at $0.50 falling short of the estimated $0.53 by -5.66%, while revenue for the quarter reached $121.70M , beating expectations by +1.28%.
Earnings released on 2 Nov 2020
EPS came in at $0.25 surpassing the estimated $0.19 by +31.58%, while revenue for the quarter reached $65.32M , beating expectations by +33.33%.
HALO Stock Performance
Access detailed HALO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.